IDEXX LABORATORIES INC /DE — Director's Dealing 2021

Feb 8, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IDEXX LABORATORIES INC /DE (IDXX)
CIK: 0000874716
Period of Report: 2021-02-04

Reporting Person: SZOSTAK M ANNE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-04	Common Stock	M	5974	$64.69	Acquired	5974	Direct
2021-02-04	Common Stock	M	5902	$85	Acquired	11876	Direct
2021-02-04	Common Stock	G	11876	—	Disposed	0	Direct
2021-02-04	Common Stock	G	11876	—	Acquired	11876	Indirect
2021-02-04	Common Stock	S	2791	$488.2357	Disposed	9085	Indirect
2021-02-04	Common Stock	S	4286	$489.2292	Disposed	4799	Indirect
2021-02-04	Common Stock	S	3399	$490.6969	Disposed	1400	Indirect
2021-02-04	Common Stock	S	1100	$491.5604	Disposed	300	Indirect
2021-02-04	Common Stock	S	300	$492.3946	Disposed	0	Indirect
2021-02-05	Common Stock	G	10217	—	Disposed	0	Indirect
2021-02-05	Common Stock	G	10217	—	Acquired	10217	Indirect
2021-02-04	Common Stock	G	10217	—	Disposed	0	Indirect
2021-02-05	Common Stock	G	10217	—	Acquired	10217	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-04	Non-Qualified Stock Option (right-to-buy)	$64.69	M	5974	Disposed	2024-05-06	Common Stock (5974)	Direct
2021-02-04	Non-Qualified Stock Option (right-to-buy)	$85	M	5902	Disposed	2026-05-03	Common Stock (5902)	Direct

Footnotes

F1: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust.

F2: Represents the weighted average price of the shares sold ranging from a low of $488.00 to a high of $489.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F3: Represents the weighted average price of the shares sold ranging from a low of $489.01 to a high of $490.01 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F4: Represents the weighted average price of the shares sold ranging from a low of $490.02 to a high of $491.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F5: Represents the weighted average price of the shares sold ranging from a low of $491.05 to a high of $492.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F6: Represents the weighted average price of the shares sold ranging from a low of $492.31 to a high of $492.46 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.

F7: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein.

F8: Grant of option to buy 2,987 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 7, 2015 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.

F9: Grant of option to buy 5,902 shares of IDEXX Laboratories, Inc. common stock that became exercisable in one installment on May 4, 2016.

F10: Not applicable.